|
US2021032356A1
|
|
Method for treating seizures
|
|
WO2020168036A1
|
|
Pic1 variants with improved solubility and methods of using the same
|
|
WO2020092990A1
|
|
Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
|
|
WO2020086705A2
|
|
Pharmaceutical compositions and methods of making on demand solid dosage formulations
|
|
WO2019236658A2
|
|
Pic1 peptide compositions and methods of use thereof for treatment of drug-induced immune hemolytic anemia
|
|
EP3419604A1
|
|
An improved formulation of long-acting levonorgestrel butanoate injectable depot suspension
|
|
US2019048365A1
|
|
Mitochondrial microinjection of oocytes
|
|
EP3054936A1
|
|
4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
|
|
EP3453717A1
|
|
Peptide compounds to regulate the complement system
|
|
AU2011255627A1
|
|
Inhibitors of human 12-lipoxygenase
|
|
EP2364155A1
|
|
Activation and aggregation of human platelets and formation of platelet gels by nanosecond pulsed electric fields
|
|
CA2706860A1
|
|
Magnaretractor system and method
|
|
AU2007221182A1
|
|
Nanosecond pulsed electric fields cause melanomas to self-destruct
|
|
AU2005274726A1
|
|
Biomarkers for bladder cancer
|
|
AU2003224767A1
|
|
Suramin and derivatives thereof as topical microbicide and contraceptive
|
